Lode Schuerman

6.5k citations
118 papers · 5.4k · 1 hit paper · h-index 37

Impact in

  • Microbiology top 0.05%
    • Bacterial Infections and Vaccines
  • Epidemiology top 0.5%
    • Pneumonia and Respiratory Infections
    • Respiratory viral infections research
    • Influenza Virus Research Studies
    • Pneumocystis jirovecii pneumonia detection and treatment

Papers in

  • Microbiology 57
    • Bacterial Infections and Vaccines 57
  • Epidemiology 73
    • Pneumonia and Respiratory Infections 68
    • Respiratory viral infections research 20
    • Influenza Virus Research Studies 15
Co-authors
Roman Prymula (11 shared papers)Patricia Lommel (14 shared papers)JAN T. POOLMAN (11 shared papers)Dorota Borys (33 shared papers)Pavla Kriz (4 shared papers)Viktor Chrobok (3 shared papers)Igor Kohl (3 shared papers)Elena Nováková (2 shared papers)
Journals
Vaccine (26 papers)The Pediatric Infectious Disease Journal (21 papers)Human Vaccines & Immunotherapeutics (10 papers)Expert Review of Vaccines (5 papers)The Lancet Global Health (4 papers)
Partner nations
BelgiumUnited KingdomFinland

In The Last Decade

Lode Schuerman

117 papers receiving 5.0k citations

Lode Schuerman's Hit Papers

Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study 2006 · 535 citations
5350+6+13Years since publication100200300400500
What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

  1. 2006 The Lancet

Peers

Lode Schuerman
Comparison fields: 5 of 104
  • Microbiology 2.2k
  • Epidemiology 3.8k
  • Otorhinolaryngology 229
  • Health 240
  • Infectious Diseases 543
Replace Roman Prymula with:
Roman Prymula Czechia
David P. Greenberg United States
Noga Givon‐Lavi Israel
Jill G. Hackell United States
Aino K. Takala Finland
Catherine Lexau United States
Jon S. Abramson United States
David Greenberg Israel
Janet R. Gilsdorf United States
Delois M. Jackson United States
Lode Schuerman relative to Roman Prymula Czechia Roman Prymula's profile →
Citations per field
00.5×1.5×
Roman Prymula · 1×
Citations per year

Countries citing papers authored by Lode Schuerman

Since Specialization
Citations

This map shows the geographic impact of Lode Schuerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lode Schuerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lode Schuerman more than expected).

Fields of papers citing papers by Lode Schuerman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lode Schuerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lode Schuerman. The network helps show where Lode Schuerman may publish in the future.

Co-authors

The 25 scholars most cited alongside Lode Schuerman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lode Schuerman Line = papers co-authored together Lode Schuerman links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 118 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study
The Lancet ·Roman Prymula, Pascal Peeters, Viktor Chrobok, Pavla Kriz, Elena Nováková, Eva Kaliskova, Igor Kohl, Patricia Lommel
Hit paper breakdown →		2006535
2
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non‐typable Haemophilus influenzae: a randomised double‐blind efficacy study
Clinical Otolaryngology ·Roman Prymula, Pascal Peeters, Viktor Chrobok, Pavla Kriz, Elena Nováková, Eva Kaliskova, Igor Kohl, Patricia Lommel
2006485
3
Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials
The Lancet ·Roman Prymula, Claire‐Anne Siegrist, Roman Chlíbek, Helena Žemličková, M Vacková, Jan Smetana, Patricia Lommel, Eva Kaliskova
2009270
4
Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine
The Pediatric Infectious Disease Journal ·Timo Vesikari, Jacek Wysocki, Bertrand Chevallier, Aino Karvonen, Hanna Czajka, Jean-Pierre Arsène, Patricia Lommel, Ilse Dieussaert
2009221
5
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial
The Lancet ·ARTO A. I. PALMU, Jukka Jokinen, Dorota Borys, Heta P. Nieminen, Esa Ruokokoski, Lotta Siira, Taneli Puumalainen, Patricia Lommel
2012192
6
Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial
PLoS Medicine ·Miguel Tregnaghi, Xavier Sáez‐Llorens, Pio López López, Héctor José Abate, Enrique Smith, Adriana Pósleman, Arlene E. Calvo, Digna Wong
2014192
7
10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix™
Expert Review of Vaccines ·Roman Prymula, Lode Schuerman
2009128
8
Neonatal Vaccination with an Acellular Pertussis Vaccine Accelerates the Acquisition of Pertussis Antibodies in Infants
The Journal of Pediatrics ·Markus Knuf, Heinz-Joesf Schmitt, Joanne M. Wolter, Lode Schuerman, Jeanne‐Marie Jacquet, Dorothee M. Kieninger, Claire‐Anne Siegrist, Fred Zepp
2007121
9
Effects of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugate Vaccine on Nasopharyngeal Bacterial Colonization in Young Children: A Randomized Controlled Trial
Clinical Infectious Diseases ·Menno R. van den Bergh, Judith Spijkerman, Kristien Swinnen, Nancy François, Thierry G. Pascal, Dorota Borys, Lode Schuerman, E. P. F. IJzerman
2012118
10
Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children
Vaccine ·Isabelle Henckaerts, Nathalie Durant, Dany De Grave, Lode Schuerman, JAN T. POOLMAN
200692
11
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study
The Lancet Infectious Diseases ·Paul Goepfert, Bo Fu, Anne-Laure Chabanon, Matthew I Bonaparte, Matthew Davis, Brandon J. Essink, Ian Frank, Owen Haney
202192
12
Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?
BMC Pediatrics ·William P. Hausdorff, Bernard Hoet, Lode Schuerman
201083
13
Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age
Vaccine ·Roman Prymula, Pavla Kriz, Eva Kaliskova, Thierry G. Pascal, JAN T. POOLMAN, Lode Schuerman
200980
14
Immunity to Pertussis 5 Years after Booster Immunization during Adolescence
Clinical Infectious Diseases ·Kati Edelman, Qiushui He, Juuso I. Mäkinen, Anna Sahlberg, Marjo Haanperä, Lode Schuerman, J. M. Wolter, Jussi Mertsola
200779
15
Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) When Coadministered With Different Neisseria meningitidis Serogroup C Conjugate Vaccines
The Pediatric Infectious Disease Journal ·Jacek Wysocki, Juan Carlos Tejedor Torres, Dutlef Grunert, Ryszard Konior, José García-Sicilia, Markus Knuf, Laurence Bernard, Ilse Dieussaert
200979
16
The 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Coadministered With DTPw-HBV/Hib and Poliovirus Vaccines: Assessment of Immunogenicity
The Pediatric Infectious Disease Journal ·Nancy Bermal, Leszek Szenborn, Andrzej Chrobot, Edison R. Alberto, Patricia Lommel, SALVACION R. GATCHALIAN, Ilse Dieussaert, Lode Schuerman
200979
17
Impact of the Conjugation Method on the Immunogenicity of Streptococcus pneumoniae Serotype 19F Polysaccharide in Conjugate Vaccines
Clinical and Vaccine Immunology ·JAN T. POOLMAN, Carl E. Frasch, Anu Nurkka, Helena M. Käyhty, Ralph Biemans, Lode Schuerman
201078
18
Immunogenicity of Routinely Used Childhood Vaccines When Coadministered With the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV)
The Pediatric Infectious Disease Journal ·Markus Knuf, Leszek Szenborn, Masnuel Moro, Christian J. Petit, Nancy Bermal, Laurence Bernard, Ilse Dieussaert, Lode Schuerman
200977
19
Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3–4 trial
The Lancet Infectious Diseases ·ARTO A. I. PALMU, Jukka Jokinen, Heta P. Nieminen, Hanna Rinta‐Kokko, Esa Ruokokoski, Taneli Puumalainen, Dorota Borys, Patricia Lommel
201377
20
Immunogenicity and Reactogenicity of Four Doses of Diphtheria-Tetanus-Three-Component Acellular Pertussis-Hepatitis B-Inactivated Polio Virus-Haemophilus influenzae Type b Vaccine Coadministered with 7-Valent Pneumococcal Conjugate Vaccine
The Pediatric Infectious Disease Journal ·Irmingard Tichmann-Schumann, Peter Soemantri, Ulrich Behre, Johann Disselhoff, H. R. Mahler, Gudrun Maechler, Roland Sänger, Jeanne‐Marie Jacquet
200574

About Lode Schuerman

Lode Schuerman is a scholar working on Microbiology, Epidemiology, Hepatology, Infectious Diseases and Public Health, Environmental and Occupational Health, having authored 118 papers that have together received 5.4k indexed citations. Recurring topics across this work include Pneumonia and Respiratory Infections (68 papers), Bacterial Infections and Vaccines (57 papers), Respiratory viral infections research (20 papers), Influenza Virus Research Studies (15 papers), Malaria Research and Control (11 papers), SARS-CoV-2 and COVID-19 Research (6 papers), Hepatitis Viruses Studies and Epidemiology (6 papers) and Hepatitis C virus research (5 papers). The work is most often cited by research in Microbiology (2.2k citations), Epidemiology (3.8k citations), Otorhinolaryngology (229 citations), Health (240 citations) and Infectious Diseases (543 citations). Lode Schuerman has collaborated with scholars based in Belgium, United Kingdom and Finland. Frequent co-authors include Roman Prymula, Patricia Lommel, JAN T. POOLMAN, Dorota Borys, Pavla Kriz, Viktor Chrobok, Igor Kohl, Elena Nováková, Ilse Dieussaert and Markus Knuf. Their work appears in journals such as Vaccine, The Pediatric Infectious Disease Journal, Human Vaccines & Immunotherapeutics, Expert Review of Vaccines and The Lancet Global Health.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roman PrymulaBreakdown of academic impact, for papers by David P. GreenbergBreakdown of academic impact, for papers by Noga Givon‐LaviBreakdown of academic impact, for papers by Jill G. HackellBreakdown of academic impact, for papers by Aino K. TakalaBreakdown of academic impact, for papers by Catherine LexauBreakdown of academic impact, for papers by Jon S. AbramsonBreakdown of academic impact, for papers by David GreenbergBreakdown of academic impact, for papers by Janet R. GilsdorfBreakdown of academic impact, for papers by Delois M. Jackson